Glutamate and schizophrenia and the n-methyl-d-aspartate receptor hypofunction hypothesis

Dopamine and Glutamate in Psychiatric Disorders

Volumn , Issue , 2005, Pages 169-179

  Bleich, Stefan ^a   Kornhuber, Johannes ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947680928     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-852-6_7     Document Type: Chapter

References (89)

1. Baron M, Grün R, Rainer JD. A family study of schizophrenic and normal control probands: implications for the spectrum concept of schizophrenia. Am J Psychiatry 1985; 142: 447-455.
2. Gottesman JJ, Shields H. Schizophrenia, the Epigenetic Puzzle. Cambridge: Cambridge University Press, 1982.
3. Heston LL. Psychiatric disorders in faster home reared children of schizophrenic mothers. Br J Psychiatry 1966; 112:819-827.
4. Carlsson A, Lindquist M. Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine and normetanophrine in mouse brain. Acta Pharmacol 1963; 20:140-144.
5. Bandelow B, Bleich S, Kropp S. Handbuch Psychopharmaka. Göttingen, Germany:Hogrefe-Verlag, 2000.
6. Owen F, Cross AJ, Crow TJ, Longden A, Poulter M, Riley GJ. Increased dopamine-receptor sensitivity in schizophrenia. Lancet 1978; 2(8083):223-226.
7. Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365(6445):441-445.
8. Farde L, Wiesel FA, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 1990; 47:213-219.
9. Roberts DA, Balderson D, Pickering-Brown SM, Deakin JF, Owen F. The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls. Schizophr Res 1996; 20:171-174.
10. 3H-Spiperone binding sites in postmortem brains from schizophrenic patients:relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 1989; 75:1-10.
11. Terenius L, Wahlström A, Lindström L, Widerlov E. Increased CSF levels of endorphins in chronic psychoses. Neurosci Lett 1976; 3:157-162.
12. Feldberg W. Possible association of schizophrenia with a disturbance in prostaglandin metabolism. A physiological hypothesis. Psychol Med 1976; 6:359-369.
13. Horrobin DF Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; I: 936-937.
14. Crow TJ. A re-evaluation of the viral hypothesis: is psychosis the result of retroviral integration at a side close to the cerebral dominance gene? Br J Psychiatry 1984; 145:243-253.
15. Reynolds GP. Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. Br J Psychiatry 1989; 155:305-316.
16. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993; 19:371-429.
17. Kornhuber J, Weller M. Aktueller Stand der biochemischen Hypothesen zur Pathogenese der Schizophrenien. Nervenarzt 1994; 65:741-754.
18. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B. Low cerebrospinal fluid gluta-mate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20:379-382.
19. Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME. Zur biochemischen Theorie der Schizophrenie. Nervenarzt 1984; 55:602-606.
20. Kornhuber J, Thome J, Riederer P. Modellvorstellungen zur Ätiopathogenese der Schizophrenien. In: Riederer P, Laux G, Pöldinger W, eds. Neuro-Psychopharmaka, Bd. 4, 2. Auflage. Wien: Springer Verlag, 1998.
21. Kornhuber ME, Kornhuber J, Zettlmeissl H, Kornhuber HH. Phencyclidin und das gluta-materge System. In: Keupp W, ed. Biologische Psychiatrie, Forschungsergebnisse. Berlin: Springer Verlag, 1986:176-180.
22. Carlsson A, Waters N, Hansson LO. Neurotransmitter aberrations in schizophrenia: new findings. In:Fog R, Gerlach J, Hemmingsen R, eds. Schizophrenia. An Integrated View. Copenhagen: Munksgaard, 1995:332-340.
23. Svensson A, Carlsson ML, Carlsson A. Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamatergic function with respect to psychomotor control. J Neural Transm 1992; 88:235-240.
24. Tsai G, Passani LA, Slusher BS, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995; 52:829-836.
25. Korpi ER, Kaufmann CA, Marnela KM, Weinberger DR. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res 1987; 20:337-345.
26. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993; 150:1731-1733.
27. Serval V, Galli T, Cheramy A, Glowinski J, Lavielle S. In vitro and in vivo inhibition of Af-acetyl-L-aspartyl-L-glutamate catabolism by,/V-acylated L-glutamate analogs. J Pharmacol Exp Ther 1992; 260:1093-1100.
28. Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the A'-methyl-D-aspartate receptor hypo-function hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60:572-576.
29. Kornhuber J, Bleich S. Memantin. In: Riederer P, Laux G, Pöldinger W, eds. Neuro-Psychopharmaka. Wien: Springer, 1999:687-704.
30. Kornhuber J, Weller M. Psychotogenicity and NMDA receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997; 41:135-144.
31. Pearlson GD. Psychiatric and medical syndromes with phencyclidine (PCP) abuse. Johns Hopkins Med J 1981; 148:25-33.
32. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301-1308.
33. Aparicio-Legarza MI, Davis B, Hutson PH, Reynolds GP. Increased density of glutamate/Af-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci Lett 1998; 241:43-146.
34. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic glutamate receptors and expression of,/V-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 2000;157:1141-1149.
35. Eastwood SL, Burnet PW, Harrison PJ. GluR2 glutamate receptor subunit flip and flop iso-forms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study. Brain Res Mol Brain Res 1997; 44:92-98.
36. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviours related to schizophrenia. Cell 1999; 98:427-436.
37. Ballard TM, Pauly-Evers M, Higgins GA, et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 2002; 22:6713-6723.
38. Sakimura K, Kutsuwada T, Ito I, et al. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature 1995; 373:151-155.
39. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci 2001; 21:750-757.
40. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 2000; 31:288-294.
41. Eastwood SL, Kerwin RW, Harrison PJ. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-A'-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry 1997; 41:636-643.
42. Harrison PJ, McLaughlin D, Kerwin RW. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 1991; 337:450-452.
43. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 1990; 39:25-32.
44. Porter RH, Eastwood SL, Harrison PJ. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res 1997; 751:217-231.
45. Deakin JF, Slater P, Simpson MD, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989; 52:1781-1786.
46. 3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 1983; 40:245-250.
47. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989; 166:589-590.
48. Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996; 16:19-30.
49. Grimwood S, Slater P, Deakin JF, Hutson PH. NR2Bcontaining NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport 1999; 10:461-465.
50. Nudmamud S, Reynolds GP Increased density of glutamate/W-methyl-D- aspartate receptors in superior temporal cortex in schizophrenia. Neurosci Lett 2001; 304:9-12.
51. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res 1995; 674:82-90.
52. Noga JT, Hyde TM, Herman MM, et al. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 1997; 27:168-176.
53. Sucher NJ, Akbarian S, Chi CL, et al. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J Neurosci 1995; 15:6509-6520.
54. Cartmell J, Monn JA, Schoepp DD. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 2000; 148:423-429.
55. Grauer SM, Marquis KL. Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology 1999; 141:405-412.
56. Crook JM, Akil M, Law BC, Hyde TM, Kleinman JE. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol Psychiatry 2002; 7:157-164.
57. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 1998; 56:207-217.
58. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 2000; 47:22-28.
59. Devon RS, Anderson S, Teague PW, et al. The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 2001; 6:311-314.
60. Bolonna AA, Kerwin RW, Munro J, Arranz MJ, Makoff AJ. Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophr Res 2001; 47:99-103.
61. Joo A, Shibata H, Ninomiya H, Kawasaki H, Tashiro N, Fukumaki Y. Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia. Mol Psychiatry 2001; 6:186-192.
62. Ohtsuki T, Toru M, Arinami T. Mutation screening of the metabotropic glutamate receptor mGluR4 (GRM4) gene in patients with schizophrenia. Psychiatr Genet 2001; 11:79-83.
63. Jia Z, Lu Y, Henderson J, Taverna F, et al. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem 1998; 5:331-343.
64. Pisani A, Gubellini P, Bonsi P, et al. Metabotropic glutamate receptor 5 mediates the potentiation of,/V-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 2001; 106:579-587.
65. Moghaddam B, Adams BW. Reversal of phencyclidine effects by group II metabotropic glutamate receptor agonist in rats. Science 1998; 281:1349-1352.
66. Costa J, Khaled E, Sramek J, Bunney W Jr, Potkin SG An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Psychophar-macol 1990; 10:71-72.
67. Waziri R. Glycine therapy of schizophrenia. Biol Psychiatry 1988; 23:210-211.
68. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56:29-36.
69. Simeon J, Fink M, Itil TM, Ponce D. D-Cycloserine therapy of psychosis by symptom provocation. Compr Psychiatry 1970; 11:80-88.
70. Cascella NG, Macciardi F, Cavallini C, Smeraldi E. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm Gen Sect 1994; 95:105-111.
71. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151:1234-1236.
72. Javitt DC, Balla A, Sershen H, Lajtha A. A.E. Bennett Research Award. Reversal of phency-clidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 1999; 45:668-679.
73. Trist DG Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications. Pharm Acta Helv 2000; 74:221-229.
74. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 2002; 159:480-482.
75. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schönfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56:21-27.
76. Millan MJ. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Target CNS Neurol Disord 2002; 1:191-213.
77. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsy-chopharmacology 1988; 1:179-186.
78. Karson CN, Casanova MF, Kleinman JE, Griffin WST. Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993; 150:454-459.
79. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989; 46:745-753.
80. Garbutt JC, van Kammen DP. The interaction between GABA and dopamine: implications for schizophrenia. Schizophr Bull 1983; 9:336-353.
81. Meltzer H Y. Clinical studies on the mechanism of action of clozapine: the dopamine-sero-tonin hypothesis of schizophrenia. Psychopharmacology 1989; 99:S18-S27.
82. Deckert J, Gleiter CH. Adenosinergic psychopharmaceuticals: just an extra cup of coffee? J Psychopharmacol 1990; 4:183-187.
83. Nair NPV, Lal S, Bloom DM (1994). Cholecystokinin and schizophrenia. In: van Ree JM, Matthysse S, eds. Progress in Brain Research. Vol. 65. Amsterdam: Elsevier, 1994:237-258.
84. Wiegant VM, Ronken E, Kovács G, de Wied D. Endorphins and schizophrenia. Prog Brain Res 1992; 93:433-453.
85. Bissette G, Nemeroff CB (1988). Neurotensin and the mesocorticolimbic dopamine system. Ann NY Acad Sci 1988; 537:397-404.
86. Olney JW, Labruyere J, Price MT. Pathologival changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989; 244:1360-1362.
87. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev 1990; 42:355-402.
88. Hudson CJ, Young LT, Li PP, Warsh JJ. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993; 13:278-293.
89. Gross G, Huber G. Sensorische Störungen bei Schizophrenien. Arch Psychiatr Nervenkr 1972; 216:119-130.